Durapain in symptomatic treatment of severe acute pain: a post-marketing, prospective, multicenter, observational study – PRIME study
| Autor: | S Subbaiah, Palash Gupta, Gauri Billa, Zubair H Sorathia, R Hom Chaudhuri, Shreedhar S Kulkarni, Ranjan Kamilya, Omvijay B Chaudhari, Kshitij Shah |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
business.industry
tramadol and diclofenac combination Fixed-dose combination Diclofenac Sodium Urine medicine.disease 03 medical and health sciences 0302 clinical medicine Anesthesiology and Pain Medicine Durapain Tolerability Anesthesia Clinical endpoint Medicine Tramadol Hydrochloride Observational study 030212 general & internal medicine Journal of Pain Research business 030217 neurology & neurosurgery Adverse drug reaction severe acute pain Original Research |
| Zdroj: | Journal of Pain Research |
| ISSN: | 1178-7090 |
| Popis: | Kshitij Shah,1 Omvijay B Chaudhari,2 Palash Gupta,3 R Hom Chaudhuri,4 Ranjan Kamilya,5 Shreedhar S Kulkarni,6 S Subbaiah,7 Zubair H Sorathia,8 Gauri Billa9 1MS Orthopedic, Prime Hospital, Andheri (West), 2Vatsalya Nursing Home, Kalyan (West), Mumbai, 3Dr.Palash Gupta Clinic, Rohini, New Delhi, 4Homchaudhuri’s Clinic, 5Apollo Gleneagles Hospital, Kolkata, West Bengal, 6Amrit Clinic, Matunga, Mumbai, 7Subbaiah’s Clinic, West Mambalam, Chennai, 8Medicare Hospital, Marol, Andheri East, 9MedicalServices, Abbott Healthcare Pvt. Ltd, Mulund (West), Mumbai, Maharashtra, India Objective: To assess the effectiveness, overall tolerability, and gastrointestinal (GI) tolerability of Durapain (fixed dose combination of tramadol hydrochloride immediate release [50 mg] and diclofenac sodium sustained release [75 mg]) in symptomatic treatment of severe acute pain in physician’s routine clinical practice. Materials and methods: In this prospective, multicenter, observational, post-marketing study, adult patients (aged 18–60 years) with severe acute pain were treated with tramadol hydrochloride/diclofenac sodium as per approved prescribing information. Evaluation was done at baseline, day 2, and day 5. Primary end point was pain intensity difference from baseline to day 5. Results: A total of 351 patients (mean age 44.2 years; male 43%; female 57%) were included. The mean pain score was reduced from 9.2±1.09 at baseline to 2.8±1.73 at day 5 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|